Cost-effectiveness of the Floodlight^® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis

Digital Health, Год журнала: 2025, Номер 11

Опубликована: Янв. 1, 2025

Objective Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting 2.9 million people worldwide, often leading to permanent disability. MS patients frequently use eHealth tools due their relatively young age. The Floodlight ® app scientifically designed smartphone application that helps monitor hand motor skills, walking ability and cognition between medical appointments. This study assesses the cost-effectiveness of using alongside standard-of-care (SoC) versus SoC alone in with relapsing-remitting (RRMS) from perspective healthcare system. Methods A 10-year decision-analytic model was developed assess incorporating SoC. analysis included treatment-naive individuals those already on drug therapy, modelling app's role early detection progression relapses improve quality-of-life. Results For patients, resulted 2,660 € increase total costs but yielded potential medical-cost savings 786 through health improvements. These experienced fewer slower disability progression, translating quality-of-life improvement 4.5 months perfect an incremental-cost-effectiveness-ratio (ICER) 7,071 €. Pre-treated showed similar trends, 718 €, ICER 7,864 4.2 months. Higher effectiveness (+5%) led additional 8.3 reduction overall costs. Conclusion demonstrates cost-effective digital application, encouraging broader discussions maximizing software-as-medical-devices within care pathway.

Язык: Английский

---

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT

Nature Reviews Neurology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 15, 2025

Язык: Английский

---

Differential gene expression in B cells and T helper cells following high-dose glucocorticoid therapy for multiple sclerosis relapse

Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 175, С. 116721 - 116721

Опубликована: Май 14, 2024

Despite remarkable advances in the therapy of multiple sclerosis (MS), patients with MS may still experience relapses. High-dose short-term methylprednisolone (MP) remains standard treatment acute management relapses due to its potent anti-inflammatory and immunosuppressive properties. However, there is a lack studies on cell type-specific transcriptome changes that are induced by this synthetic glucocorticoid (GC). Moreover, it not well understood why some do benefit adequately from MP therapy.

Язык: Английский

---

Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies

Multiple Sclerosis and Related Disorders, Год журнала: 2025, Номер 94, С. 106263 - 106263

Опубликована: Янв. 7, 2025

Язык: Английский

---

Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study

Neurotherapeutics, Год журнала: 2025, Номер unknown, С. e00537 - e00537

Опубликована: Янв. 1, 2025

Ocrelizumab (OCR) and Natalizumab (NTZ) are highly effective treatments widely used in Multiple Sclerosis (MS). However, long-term, real-world comparative data on clinical effectiveness, safety treatment persistence limited. This retrospective analysis included relapsing progressive MS patients initiating at two Italian Universities ("La Sapienza" "Federico II"). Propensity-score nearest-neighbor matching with a caliper of 0.1 was conducted to adjust for between-group differences age, sex, previous status, phenotype, disease duration, MRI activity baseline. Differences follow-up duration were adjusted pairwise censoring. Cox proportional hazard regression models Evidence (EDA-3) its components (relapses, activity, confirmed disability progression) as outcomes. Treatment discontinuation rate occurrence adverse events (AEs) tested using logistic regression. We identified 308 (140 OCR, 168 NTZ) mean (SD) 75.7 (30.8) months. Patients treated OCR older less active frequenlty naïve baseline than NTZ-treated patients. The PS-matching procedure retained 140 (70 pairs) 55.9 (14.3) No significant found between NTZ terms relapses, or progression. associated higher incidence mild moderate AEs, comparable persistence. study provides evidence effectiveness over 5-year observation period, being AEs and, possibly,

Язык: Английский

---

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis

S S Korsakov Journal of Neurology and Psychiatry, Год журнала: 2025, Номер 125(2), С. 58 - 58

Опубликована: Март 6, 2025

To compare efficacy of the new drug divozilimab with other second-line treatment options for relapsing remitting multiple sclerosis (RRMS) that have been already included or submitted application to be into «14 high-cost nosologies» program in Russian Federation. We conducted systematic literature review (PROSPERO ID CRD42022310082) and frequentist network meta-analysis 2-years therapies treat RRMS. Annualized relapse rate ratio vs fingolimod was 0.4 (95% CI 0.3-0.7), cladribin 0.5 0.3-0.9), alemtuzumab 0.7 0.3-1.7), ocrelizumab 0.3-1.6), ofatumumab 0.4-1.1), natalizumab 0.4-1.1) respectively. Divozilimab had highest SUCRA rank (0.9) while lowest (0.4). Systematic revealed statistically significant superiority over cladribine absence differences alemtuzumab, ocrelizumab, annual during 2 years treatment.

Язык: Английский

---

Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model

ClinicoEconomics and Outcomes Research, Год журнала: 2025, Номер Volume 17, С. 217 - 232

Опубликована: Март 1, 2025

Ofatumumab, a fully human anti-CD20 monoclonal antibody, is promising disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS). This study investigates its cost-effectiveness compared to teriflunomide from the perspective of Saudi healthcare payers. comparison crucial informing treatment strategies and resource allocation in Arabia, where RRMS poses significant burden access newer DMTs evolving. A Markov model was constructed evaluate long-term ofatumumab treating Arabia. simulates disease progression over 10 years, timeframe chosen clinical relevance consistency with similar studies. To reflect patient population, uses hypothetical cohort characteristics mirroring those ASCLEPIOS I/II trials. The incorporates transition probabilities between states, primarily derived British Columbia MS (BCMS) database further refined using data ensure context, local sources were utilized, including drug costs Food Drug Authority (SFDA) health state published Clinical expert input incorporated validate assumptions.The primary outcome measure incremental cost per quality-adjusted life-year (QALY) gained. Sensitivity analyses conducted assess robustness findings. Compared teriflunomide, yielded ratios (ICERs) $46,188 QALY 10-year period. Ofatumumab demonstrated greater impact on reducing disability progression, particularly early stages disease. At willingness-to-pay (WTP) threshold $99,120 QALY, 99.14% probability probabilistic sensitivity analyses. analysis demonstrates that cost-effective an ICER below WTP. Policymakers should consider national formularies prioritize use early-stage maximize benefit cost-effectiveness.

Язык: Английский

---

Overview of Metformin and Neurodegeneration: A Comprehensive Review

Pharmaceuticals, Год журнала: 2025, Номер 18(4), С. 486 - 486

Опубликована: Март 28, 2025

This comprehensive review examines the therapeutic potential of metformin, a well-established diabetes medication, in treating neurodegenerative disorders. Originally used as first-line treatment for type 2 diabetes, recent studies have begun investigating metformin’s effects beyond metabolic disorders, particularly its neuroprotective capabilities against conditions like Parkinson’s disease, Alzheimer’s Huntington’s and multiple sclerosis. Key findings demonstrate that operate through pathways: AMPK activation enhancing cellular energy metabolism autophagy; upregulation antioxidant defenses; suppression inflammation; inhibition protein aggregation; improvement mitochondrial function. These mechanisms collectively address common pathological features neurodegeneration neuroinflammation, including oxidative stress, accumulation, dysfunction. Clinical preclinical evidence supporting association with improved cognitive performance, reduced risk dementia, modulation hallmarks diseases is critically evaluated. While metformin shows promise agent, this emphasizes need further investigation to fully understand optimal applications diseases.

Язык: Английский

---

Management of hepatitis B virus (HBV) infection in multiple sclerosis patients on disease modifying therapies (DMTs)

Future Virology, Год журнала: 2025, Номер unknown, С. 1 - 10

Опубликована: Апрель 2, 2025

Язык: Английский

---

Selective IgM Hypogammaglobulinemia and Multiple Sclerosis Treated with Natalizumab and Ofatumumab: A Case Report

Journal of Personalized Medicine, Год журнала: 2025, Номер 15(4), С. 155 - 155

Опубликована: Апрель 17, 2025

Background: B-cell-depleting drugs targeting the CD20 antigen have been increasingly implemented as an “exit strategy” from natalizumab for relapsing–remitting multiple sclerosis (RRMS) patients due to increased risk of progressive multifocal leukoencephalopathy. Data on recently approved anti-CD20 drugs, such ofatumumab serving a strategy”, are lacking. Furthermore, their immunosuppressive mechanism action, prolonged use these “highly effective” is associated with development hypogammaglobulinemia and, consequently, higher infections. There no guidelines monitoring serum immunoglobulin levels in individuals undergoing treatment. Methods: We present case 26-year-old male RRMS patient selective IgM deficiency and initially treated later ofatumumab. Results: The achieved “no evident disease activity “status while treatment ofatumumab, but therapies, especially greatly impacted further drops levels. However, significant decrease IgG was observed, infectious events occurred. In addition, did not show signs which also offered more convenient mode administration. Conclusions: Our experience points need explore benefit–risk ratios highly effective treatments, even cases low closely conducting clinical follow-ups ensure prompt recognition potential complications constitute approaches that thought patients.

Язык: Английский

---